BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...

ISM6166 was nominated as a PCC as an oral, broad-spectrum pan‑KRAS ON/OFF inhibitor, designed to overcome resistance ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...

A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasib in KRAS-mutated colorectal cancer cells – – Data support ...